Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy

Liu, Anwei; Xue, Yongping; Liu, Fei; Tan, Haoyuan; Xiong, Qiao; Zeng, Shuxiong; Zhang, Zhensheng; Gao, Xu; Sun, Yinghao; Xu, Chuanliang

doi:10.3233/cbm-182143

Cited by 9 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As in our study, SPINK1 expression was found in umbrella cells of 52% of control cases in the normal urothelium. Lately Liu et al (2019) made a similar conclusion that a decreased SPINK1 expression correlated with more advanced disease and was positively correlated with favorable differentiation of bladder cancer, and lower tumor stage. These discrepancies of results between our study along with several others on one hand, and between other studies with different findings, on the other hand, can be explained by differences in the reliability of immunohistochemical techniques.…”

Section: Discussionmentioning

confidence: 75%

Evaluation of HER2/neu and SPINK1 as an adjunct to the prognosis of urothelial dysplasia and urothelial carcinoma of the urinary bladder

Atef

Bedeer

2021

International Journal of Cancer and Biomedical Research

View full text Add to dashboard Cite

It is with great pleasure that I write this editorial to welcome you to the IJCBR. This journal provides a platform for publication of original and reviews research articles, short communications, letter to editor, thesis abstract, conference report, and case studies. These types of publication are directed at the interface of the fields of cancer and biomedical research.The IJCBR relies on a distinguished expert of the Advisory and Editorial Board Members from the top international league covering in depth the related topics. They timely review all manuscripts and maintain highest standards of quality and scientific methodology and ethical concepts. Meanwhile, we take all possible means to keep the time of the publication process as short as possible.I take this chance to welcome your contributions to the IJCBR and have every expectation that it will soon become one of the most respected journals in both the fields of cancer and biomedical research.

show abstract

Section: Discussionmentioning

confidence: 75%

Evaluation of HER2/neu and SPINK1 as an adjunct to the prognosis of urothelial dysplasia and urothelial carcinoma of the urinary bladder

Atef

Bedeer

2021

International Journal of Cancer and Biomedical Research

View full text Add to dashboard Cite

show abstract

“…Liu [26] made a similar conclusion that a decrease in the TATI expression correlated with a more advanced disease. Moreover, in the progression of bladder cancer, the prognostic value of a p53 overexpression can be enhanced by TATI.…”

Section: Tumor-associated Trypsin Inhibitor (Tati)mentioning

confidence: 67%

“…No data [26] Study cohort consisted of 160 patients, divided into 3 groups. Group 1 had 80 primary HG UBC.…”

Section: Tissue Microarrays From Ucb (N = 110)mentioning

confidence: 99%

Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers

Matuszczak

Salagierski

2020

IJMS

View full text Add to dashboard Cite

The high occurrence of bladder cancer and its tendency to recur in combination with a lifelong surveillance make the treatment of superficial bladder cancer one of the most expensive and time-consuming. Moreover, carcinoma in situ often leads to muscle invasion with an unfavorable prognosis. Currently, invasive methods including cystoscopy and cytology remain a gold standard. The aim of this study was to explore urine-based biomarkers to find the one with the best specificity and sensitivity, which would allow optimizing the treatment plan. In this review, we sum up the current knowledge about Cytokeratin fragments (CYFRA 21.1), Excision Repair Cross-Complementation 1 (ERCC1), Tumour Protein p53 (Tp53), Fibroblast Growth Factor Receptor 3 (FGFR3), Tumor-Associated Trypsin Inhibitor (TATI) and their potential applications in clinical practice.

show abstract

“…The main genetic alterations underlying MIBC involve structural and functional defects in the tumor suppressors encoding proteins that regulate cell cycle and apoptosis pathways, including TP53, ERBB2/HER2, PTEN, and RB1 (55,56). Several retrospective studies have suggested that nuclear accumulation of TP53 is a prognostic factor for MIBC, particularly in patients treated with radical cystectomy (57)(58)(59). However, the use of TP53 as a prognostic biomarker for MIBC has not been clinically established, despite over 100 studies evaluating its usefulness (60,61).…”

Section: Molecular Biology Of Ucc: An Overviewmentioning

confidence: 99%

The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma

Kang¹,

Kim²,

Yun³

2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Urothelial cell carcinoma (UCC) of the bladder and upper urinary tract is a heterogeneous disease with distinct biologic features resulting in different clinical behaviors. Bladder cancer (BC) is classified into non-muscle invasive BC (NMIBC) and muscle invasive BC (MIBC). NMIBC is associated with high recurrence rates and risk of progression to invasive disease, whereas MIBC is complicated by systemic recurrence after radical cystectomy because of the limited efficacy of available therapies. UCC of the upper urinary tract (UUT-UCC) is a rare but aggressive urologic cancer characterized by multifocality, local recurrence, and metastasis. Conventional histopathologic evaluation of UCC, including tumor stage and grade, cannot accurately predict the behavior of BC and UUT-UCC. Recent clinical and preclinical studies aimed at understanding the molecular landscape of UCC have provided insight into molecular subtyping, inter-or intratumoral heterogeneity, and potential therapeutic targets. Combined analysis of molecular markers and standard pathological features may improve risk stratification and help monitor tumor progression and treatment response, ultimately improving patient outcomes. This review discusses prognostic and therapeutic biomarkers for BC and UUT-UCC, and describes recent advances in molecular stratification that may guide prognosis, patient stratification, and treatment selection.

show abstract

Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy

Cited by 9 publications

References 32 publications

Evaluation of HER2/neu and SPINK1 as an adjunct to the prognosis of urothelial dysplasia and urothelial carcinoma of the urinary bladder

Evaluation of HER2/neu and SPINK1 as an adjunct to the prognosis of urothelial dysplasia and urothelial carcinoma of the urinary bladder

Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers

The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma

Contact Info

Product

Resources

About